CorMedix Inc.

NasdaqGM:CRMD 株式レポート

時価総額:US$688.7m

CorMedix 過去の業績

過去 基準チェック /06

CorMedixの収益は年間平均-7.1%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間2.1% 81.3%割合で 増加しています。

主要情報

-7.1%

収益成長率

14.8%

EPS成長率

Pharmaceuticals 業界の成長6.0%
収益成長率81.3%
株主資本利益率-78.6%
ネット・マージン-376.3%
前回の決算情報30 Sep 2024

最近の業績更新

Recent updates

Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Nov 14
Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts

Nov 04
Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts

CorMedix 2.0: New Leadership, New Approval, New Focus

Oct 28

CorMedix: Delayed Approval, Low Cash, Good Prospects

Oct 19

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Sep 30
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

Apr 06
We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Nov 02
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jul 31
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

Feb 25
CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

FDA again rejects CorMedix's application for lead candidate DefenCath, shares sink ~60%

Aug 08

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jul 16
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Mar 01
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Sep 09
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix Inc.'s (NASDAQ:CRMD) Intrinsic Value Is Potentially 58% Above Its Share Price

Feb 11
CorMedix Inc.'s (NASDAQ:CRMD) Intrinsic Value Is Potentially 58% Above Its Share Price

We're Hopeful That CorMedix (NYSEMKT:CRMD) Will Use Its Cash Wisely

Jan 04
We're Hopeful That CorMedix (NYSEMKT:CRMD) Will Use Its Cash Wisely

収支内訳

CorMedix の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGM:CRMD 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Sep 2412-46575
30 Jun 241-53516
31 Mar 240-504311
31 Dec 230-463613
30 Sep 230-402814
30 Jun 230-372513
31 Mar 230-332312
31 Dec 220-302011
30 Sep 220-291911
30 Jun 220-311813
31 Mar 220-281613
31 Dec 210-281613
30 Sep 210-271612
30 Jun 210-251510
31 Mar 210-241514
31 Dec 200-221413
30 Sep 200-211314
30 Jun 200-471213
31 Mar 200-441111
31 Dec 190-441011
30 Sep 190-3694
30 Jun 191-14910
31 Mar 191-22813
31 Dec 180-27819
30 Sep 180-39832
30 Jun 180-39829
31 Mar 180-36828
31 Dec 170-33924
30 Sep 170-29920
30 Jun 170-28921
31 Mar 170-28919
31 Dec 160-25916
30 Sep 160-22913
30 Jun 160-1898
31 Mar 160-17107
31 Dec 150-18106
30 Sep 150-17105
30 Jun 150-1784
31 Mar 150-982
31 Dec 140-2171
30 Sep 140-2271
30 Jun 140-1961
31 Mar 140-2551
31 Dec 130-1031

質の高い収益: CRMDは現在利益が出ていません。

利益率の向上: CRMDは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: CRMDは利益が出ておらず、過去 5 年間で損失は年間7.1%の割合で増加しています。

成長の加速: CRMDの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: CRMDは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 54.6% ) と比較することは困難です。


株主資本利益率

高いROE: CRMDは現在利益が出ていないため、自己資本利益率 ( -78.6% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘